AUG 10, 2026 · JOURNAL ARTICLE
How low do you need to go? Association between various prostate‐specific antigen response measures and clinical outcomes in metastatic castration‐sensitive prostate cancer in the Veterans Health Administration data
Cancer
Large real-world retrospective cohort with 4890 patients, adjusted Cox regression analysis, and hard clinical endpoint (overall survival), demonstrating that PSA nadir <0.2 ng/mL predicts OS benefit independent of percentage decline.
Reported
Sample size4890
Proportion achieving PSA <0.2 ng/…44%
Proportion achieving ≥90% PSA dec…74%